Condiciones de salud que luteolina puede ayudar a apoyar.
Luteolin is the principal anti-allergic flavonoid of Perilla frutescens, used in Asian traditional medicine for respiratory allergy. A murine HDM-induced allergic rhinitis model plus ex vivo PBMC cultures from human AR patients (Frontiers in Pharmacology, 2020) showed luteolin decreased HDM-specific IgE, reduced CD4+ IL-4-secreting T cells, lowered eosinophil infiltration, and decreased nasal mucus secretion. Multiple additional murine models confirm reduction of bronchoconstriction and airway inflammation.
Luteolin, a polyphenolic flavonoid found in fruits, vegetables, and herbs, supports antioxidant defense primarily by activating the Nrf2/HO-1 signaling pathway and directly scavenging reactive oxygen species (ROS). Preclinical studies consistently show it upregulates enzymatic antioxidants—including SOD, catalase, glutathione (GSH), and NQO1—while reducing oxidative stress biomarkers such as MDA. Evidence is robust in cell and animal models across multiple organ systems; dedicated human RCTs specifically measuring luteolin's antioxidant endpoints remain limited.
Multiple preclinical studies show luteolin reduces anxiety-like behavior through suppression of neuroinflammation, HPA axis regulation, and monoamine modulation. Animal models of sleep deprivation, PTSD, and chronic stress all demonstrate significant anxiolytic effects. Human clinical evidence remains limited, with no standalone RCTs in anxious populations yet published.
Luteolin is a flavone with documented anti-atherosclerotic properties including eNOS upregulation, endothelial protection, and inhibition of VSMC proliferation. It is found in celery, thyme, and artichoke. Multiple preclinical studies and limited clinical data support its role in improving endothelial function and reducing arterial inflammation.
Luteolin reduces inflammatory mediators and pain behaviors in preclinical models of both rheumatoid and osteoarthritis. It targets NF-κB, COX-2, and pro-inflammatory cytokines involved in joint inflammation. Preclinical evidence is robust; human data are currently lacking.
Luteolin attenuates allergic asthma in preclinical models through suppression of airway inflammation, Th2 cytokine responses, and bronchial hyperreactivity. Multiple mechanistic pathways have been identified including NF-κB and PI3K/Akt inhibition.
Luteolin, a dietary flavone found in vegetables and herbs, has documented anti-inflammatory and immunomodulatory properties studied in autoimmune diseases including RA, MS, IBD, and SLE. It inhibits NF-κB, suppresses Th17 differentiation, and promotes Treg cells. Animal studies demonstrate significant attenuation of EAE and collagen-induced arthritis.
Luteolin-containing nutraceutical combinations have shown blood pressure reduction in a human RCT in pre-obese subjects. Preclinical mechanisms include endothelial protection, anti-inflammatory effects on vascular smooth muscle, and antioxidant activity.
Luteolin has demonstrated blood glucose-lowering effects in animal models of diabetes and in a human RCT using a luteolin-containing nutraceutical combination. It acts via multiple mechanisms including improved insulin signaling and reduced hepatic lipid accumulation. Some human evidence exists from combination product trials.
Luteolin has been directly investigated for brain fog, with a 2015 Frontiers in Neuroscience review proposing it as a targeted intervention. A liposomal luteolin formulation improved attention in children with autism spectrum disorders and reduced brain fog in mastocytosis patients. A clinical study of PEA+luteolin in COVID-19 patients also showed improvements in cognitive symptoms.
Luteolin is the subject of a dedicated 2025 Frontiers in Pharmacology review on its regulatory mechanisms in inflammatory respiratory diseases. It inhibits NF-κB and PI3K/Akt pathways in bronchial inflammation models and is cited in the 2025 chronic bronchitis systematic review as a flavonoid with demonstrated effects in inflammatory respiratory conditions.
Luteolin reduces LDL-C and total cholesterol in rat hyperlipidemia models and in a human combination nutraceutical RCT. Its mechanism includes SREBP-2 suppression, reduced HMGCR transcription, and inhibition of cholesterol biosynthesis.
Luteolin, a dietary flavonoid found in vegetables and herbs, has well-documented anti-inflammatory activity across in vitro, in vivo, and limited human studies. Its primary mechanism involves suppression of the NF-κB, MAPK, AP-1, and STAT3 transcription factor pathways, reducing pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6. While preclinical evidence is robust, human clinical data remain limited, with emerging translational studies using luteolin-containing formulations showing suppression of key inflammatory biomarkers.
Luteolin demonstrates analgesic effects in preclinical models of neuropathic and inflammatory chronic pain. It reduces thermal hyperalgesia, mechanical allodynia, and pain behaviors in multiple animal pain models, and acts synergistically with standard analgesics in the PEA+luteolin combination.
Luteolin, a dietary flavone found in celery, parsley, and chamomile, has substantial preclinical evidence supporting neuroprotection and attenuation of cognitive decline via anti-inflammatory, antioxidant, and anti-amyloid mechanisms. It suppresses microglial activation and neuroinflammatory signaling pathways (NF-κB, MAPK) implicated in brain aging. Human clinical evidence is nascent — early-phase trials are underway or recently completed, but robust, published RCT results in aged or cognitively impaired populations are not yet available. The evidence base is currently strongest at the preclinical level, with clinical translation actively in progress.
Luteolin is a flavone with documented anti-influenza and anti-inflammatory activity. In vitro studies demonstrate inhibition of influenza A replication and neuraminidase activity. Luteolin is a major active constituent of thyme, forsythia, honeysuckle, and other traditional cold/flu herbs. Its NF-κB inhibitory effects reduce cold/flu-related inflammatory cytokines. Preclinical evidence is robust though clinical RCTs for isolated luteolin in cold/flu are limited.
Luteolin reduces pulmonary inflammation, oxidative stress, and alveolar damage in COPD preclinical models through NF-κB, Nrf2/HO-1, and MAPK pathway modulation. It is consistently identified as a candidate for COPD management in systematic reviews.
Luteolin demonstrates antidepressant-like effects across numerous preclinical models via multiple mechanisms including PMAT inhibition, HPA axis regulation, anti-neuroinflammation, and glycerophospholipid metabolism modulation. A 2024 systematic review identified 17 preclinical studies. Human clinical confirmation is very limited.
Luteolin has been reviewed for effects in both atopic dermatitis and contact dermatitis, demonstrating anti-inflammatory and mast cell-stabilizing effects in preclinical models. Topical formulations show promise for reducing dermal inflammation.
Luteolin reduces seizure severity, frequency, and duration in multiple animal seizure models (PTZ, kainic acid) and preserves hippocampal neuronal integrity. It modulates GADD45B, MAPK, NF-κB, and PKA/CREB/BDNF pathways. Evidence is preclinical; no human trials have been conducted.
Luteolin has been shown to improve attention in children with autism spectrum disorders using a liposomal formulation, and to reduce brain fog-related inability to concentrate in clinical observations. Preclinical evidence supports improved cognitive performance through microglia inhibition, mast cell stabilization, and neurotrophic factor support.
Luteolin is a flavone confirmed as a competitive xanthine oxidase inhibitor in vitro, with inhibitory activity comparable to or exceeding quercetin. In animal models of hyperuricemic nephropathy, luteolin activated urate excretion via ABCG2 and OAT transporters, inhibited hepatic XO, and protected renal function. Hepatocyte culture studies show luteolin reduces uric acid production more potently than quercetin.
Luteolin has been shown to enrich gut bacterial species diversity, reduce intestinal dysbiosis, and modulate the gut microbiome in preclinical NASH and metabolic syndrome models. It reduces plasma LPS and intestinal permeability, supporting a healthier gut microbial environment.
Luteolin is a flavone found in celery, broccoli, and thyme with potent anti-inflammatory, antioxidant, and senolytic properties. It inhibits NF-κB, activates Nrf2 and SIRT1, and demonstrates anti-aging effects in multiple cellular and animal models. Emerging human evidence supports luteolin for cognitive protection and inflammaging reduction.
Luteolin is a flavone with otoprotective properties demonstrated in animal studies, protecting cochlear hair cells from noise-induced and cisplatin-induced damage via antioxidant and anti-inflammatory mechanisms. It is included in the ConsumerLab-referenced Advanced Hearing Formula (25 mg per serving) alongside other evidence-based hearing ingredients.
Luteolin has been identified as a cardioprotective agent that reduces cardiac hypertrophy, fibrosis, and dysfunction in preclinical models. Human RCT data using luteolin-containing nutraceuticals show improvements in cardiovascular biomarkers including carotid-media thickness and endothelial function.
Luteolin is a flavonoid that stabilizes mast cells and inhibits histamine release, showing greater potency than cromolyn sodium in some assays. Animal studies confirm luteolin reduces histamine release from mast cells stimulated by histamine liberators. It is used in clinical practice for mast cell activation and histamine intolerance.
Luteolin and its derivative luteolin 7-sulfate inhibit CREB and MITF-mediated tyrosinase expression, reducing melanin synthesis in B16F10 cells and primary human epidermal melanocytes. Luteolin is identified in skin disorder reviews as an antimelanogenic flavonoid relevant to hyperpigmentation.
Luteolin significantly alleviates experimental colitis in preclinical models by modulating T cell differentiation, inhibiting NF-κB-driven inflammatory mediators, and improving gut microbiota structure. A systematic review and meta-analysis of preclinical evidence supports its therapeutic potential in ulcerative colitis.
Luteolin improves insulin sensitivity in animal models of diet-induced obesity and diabetes, inhibiting insulin resistance through toll-like receptor and AMPK signaling pathways. A human RCT using a luteolin-containing nutraceutical measured HOMA-IR as an endpoint.
Luteolin reduces intestinal permeability and plasma LPS in preclinical NAFLD/NASH models, enriches beneficial gut bacteria that support barrier function, and its mitochondrial-protective effects secondarily benefit epithelial tight junction integrity.
Luteolin demonstrates significant hepatoprotective effects across NAFLD, NASH, hepatic fibrosis, and liver enzyme normalization in preclinical models and is a key active component in clinically used liver-protective formulations in traditional Chinese medicine practice. Human combination-product trial data also support improvements in hepatic enzyme profiles.
Luteolin has been extensively studied for its effects across multiple pulmonary conditions, including COPD, asthma, pneumonia, and acute lung injury. It suppresses multiple inflammatory signaling pathways in lung tissue. Evidence is largely preclinical with emerging mechanistic data.
Luteolin, a widely distributed flavone, demonstrated in vitro bacteriostatic and bactericidal activity against B. burgdorferi spirochetes in a 2016 PMC study, and reduced biofilm-like colonies at 200–500 µg/ml. It also has potent NF-κB-mediated anti-inflammatory effects relevant to chronic Lyme symptoms. It is present in Thyme, lemon balm, and other Lyme-relevant herbs.
Luteolin, a flavone in celery, chamomile, and green peppers, is among the most potent natural mast cell stabilizers studied in human mast cell models, outperforming pharmaceutical cromolyn for histamine and cytokine suppression in some in vitro assays. It inhibits histamine, leukotriene, and prostaglandin D2 release concentration-dependently via Ca2+ and PKC blockade. It uniquely crosses the blood-brain barrier, making it relevant for neuroinflammatory MCAS presentations.
Luteolin consistently improves memory in animal models of scopolamine-induced amnesia and amyloid-β toxicity. A clinical study of PEA+luteolin in COVID-19 patients showed improvement in memory loss (brain fog). Luteolin induces neurotrophic factor synthesis and protects hippocampal neurons.
Luteolin addresses multiple components of metabolic syndrome including dyslipidemia, hyperglycemia, hepatic steatosis, gut dysbiosis, and mitochondrial dysfunction in preclinical models. A human combination-product RCT in pre-obese subjects showed improvements in a broad cardiometabolic panel.
Luteolin, a dietary flavone, has demonstrated significant metabolic effects in preclinical studies, including improving insulin sensitivity, reducing hyperglycemia, and alleviating hepatic steatosis through multiple signaling pathways such as AMPK, PI3K/Akt, and PPARγ. A 2025 critical review identified around 19 animal studies and 3 human studies documenting its modulation of glycolipid metabolism. Evidence in humans remains limited, and poor bioavailability is a recognized challenge. Overall, the scientific basis is real but predominantly preclinical, with clinical translation still in early stages.
Luteolin protects mitochondrial function across multiple cell types, including neurons, hepatocytes, and skin cells. It reduces mitochondrial ROS production, preserves mitochondrial membrane potential, and protects against methylmercury-induced mitochondrial damage. These effects are documented in cell and animal studies.
Luteolin is specifically identified as one of the key active flavonoids in Chinese herbal medicine formulae for MG in a 2022 Frontiers in Microbiology clinical study of 30 MG patients. The formula containing luteolin as an active compound significantly improved MG symptoms through immunomodulatory mechanisms including Treg regulation and gut microbiota modulation.
Luteolin demonstrates neuroprotective and analgesic effects in models of neuropathic pain including chronic constriction injury and sciatic nerve damage. It reduces thermal hyperalgesia and cold allodynia. The PEA+luteolin combination has clinical evidence from neuropathic pain settings.
Luteolin is a flavone found in celery, broccoli, and herbs that inhibits osteoclast differentiation and promotes osteoblast activity in preclinical studies. The Frontiers in Nutrition (2024) osteoporosis nutraceuticals review identified luteolin as a bone-protective phytochemical. It inhibits RANKL-induced osteoclastogenesis via NF-κB suppression.
Luteolin is neuroprotective in multiple Parkinson's disease cell and animal models, protecting dopaminergic neurons from MPP+, 6-OHDA, and manganese neurotoxicity via Nrf2 activation, mitochondrial protection, and neuroinflammation suppression. Evidence is preclinical; clinical data involve the PEA+luteolin combination.
Luteolin attenuates lung inflammation in bacterial and viral pneumonia models through NF-κB, TLR4, and NLRP3 inflammasome suppression. It reduces pro-inflammatory cytokine production and oxidative stress in lung tissue. Evidence is preclinical.
Luteolin is a flavone with potent anti-inflammatory, antiviral, and neuroprotective properties studied in post-COVID brain fog and mast cell activation contexts. It inhibits SARS-CoV-2 entry, reduces microglial neuroinflammation, and stabilizes mast cells. Clinical data from a study in COVID-19 brain fog patients using luteolin-containing preparation showed significant symptom improvement.
Luteolin is a flavone studied for psoriasis due to its anti-inflammatory, antioxidant, and antiproliferative properties. It suppresses NF-κB, inhibits keratinocyte proliferation, and reduces pro-inflammatory cytokines. It is identified in peer-reviewed PMC narrative reviews as having therapeutic potential in psoriasis, primarily based on preclinical evidence.
Luteolin is a flavonoid with potent mast cell-stabilizing and anti-inflammatory properties demonstrated in preclinical allergy models. It inhibits histamine release and IgE-mediated responses through NF-κB and Th2 cytokine suppression, mechanisms directly relevant to urticaria. Evidence is currently preclinical; clinical urticaria RCTs for isolated luteolin have not been published.
Luteolin reduces joint inflammation, cartilage degradation, and inflammatory cytokine production in rheumatoid arthritis preclinical models via NF-κB, MAPK, and synoviocyte apoptosis pathways. It is highlighted in multiple systematic reviews as a promising anti-RA agent.
Luteolin is a flavone that acts as a potent mast cell stabilizer and histamine release inhibitor, with anti-allergic mechanisms similar to quercetin. In vitro and animal studies demonstrate inhibition of IgE-mediated degranulation and Th2 cytokine production. It is included in evidence reviews of natural anti-allergic agents for allergic rhinitis.
Luteolin is a flavone identified as the active anti-allergic component of Perilla frutescens and found in many edible plants. In allergic rhinitis mouse models, it significantly reduced allergic symptoms, IgE, eosinophil infiltration, and IL-4-secreting T cells, and reduced CD4+IL-4-secreting cells in human AR patient PBMCs in vitro. Evidence is primarily preclinical with mechanistic support.
Luteolin reduces UVA- and UVB-induced photoaging in preclinical models, including wrinkle formation, collagen degradation, and skin epidermal thickening. It targets the SIRT3/ROS/MAPK axis and protects dermal fibroblasts from senescence.
Luteolin attenuates physiological and behavioral stress responses in animal models by normalizing HPA axis dysregulation, reducing corticosterone and ACTH levels, and suppressing neuroinflammation in hippocampal stress-processing circuits.
Luteolin provides photoprotection against both UVB and UVA radiation by reducing ROS formation, suppressing DNA damage, inhibiting MMP activation, and preserving collagen in preclinical cell and animal models. It shows promise as a topical photoprotective agent.
Luteolin-containing nutraceuticals reduced triglycerides in human RCT subjects, and preclinical data show luteolin modulates hepatic triglyceride synthesis via PPAR and SREBP pathways. Animal evidence shows mixed triglyceride effects depending on dose and model.
Luteolin is a flavone found in celery, thyme, and other plants with documented antiviral activity against influenza, SARS-CoV, ZIKA, dengue, and HIV in vitro. It inhibits viral entry and replication and modulates cytokine production. Some clinical and mechanistic data support its role in viral immune response.
Luteolin significantly attenuates blood glucose, improves impaired healing, and accelerates re-epithelization in diabetic rat wound models. It also modulates PPAR-related pathways involved in keratinocyte proliferation and epidermal barrier formation.
Luteolin is a flavonoid found in celery, parsley, and chamomile that inhibits 5-alpha reductase, reduces perifollicular inflammation, and has been shown to promote hair growth in mouse models. It acts via similar mechanisms to quercetin and other anti-androgenic flavonoids and is included in hair loss research as a naturally occurring DHT blocker.
Volver